World Age-Related Macular Degeneration Pipeline Report 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Age-Related Macular Degeneration Pipeline Highlights - 2017" drug pipelines to their offering.

Age-Related Macular Degeneration Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Age-Related Macular Degeneration market. It covers emerging therapies for Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Age-Related Macular Degeneration pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Age-Related Macular Degeneration pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Age-Related Macular Degeneration pipeline products by the company.

Short-term Launch Highlights:

Find out which Age-Related Macular Degeneration pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Age-Related Macular Degeneration Pipeline by Stages

2. Age-Related Macular Degeneration Pipeline by Drug Class

3. Age-Related Macular Degeneration Pipeline by Company

4. Age-Related Macular Degeneration Phase 3 Clinical Trial Insights

5. Age-Related Macular Degeneration Phase 2 Clinical Trial Insights

6. Age-Related Macular Degeneration Phase 1 Clinical Trial Insights

7. Age-Related Macular Degeneration Preclinical Research Insights

8. Age-Related Macular Degeneration Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/sn6lf8/agerelated

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical , Optical Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical , Optical Disorders Drugs